Melbourne will host the inaugural International Psychedelic Roundtable Symposium ( PRS 27 ) , on 20 March 2027, bringing together psychiatrists, psychologists, clinicians, researchers, healthcare executives, investors, media representatives and industry leaders from Australia and overseas.
The event comes at a time of growing international interest in psychedelic-assisted therapies, mental health innovation and emerging approaches to psychiatric care. As research continues to expand and regulatory frameworks evolve around the world, demand for professional forums that bring together clinicians, researchers, policymakers, investors and industry stakeholders has increased significantly.
Organisers say the symposium has been designed to provide a professional platform for discussion, education and collaboration across a broad range of disciplines connected to mental healthcare and psychedelic medicine.
The industry event will explore developments in psychiatry, psychology, neuroscience, clinical research, healthcare policy, workforce development, patient access, regulation, investment trends, commercialisation and the future role of psychedelic-assisted therapies within modern healthcare systems.
Australia has attracted considerable international attention in recent years following the Therapeutic Goods Administration’s decision to permit authorised psychiatrists to prescribe MDMA and psilocybin for specific psychiatric conditions under carefully regulated circumstances. The decision placed Australia at the forefront of a global conversation surrounding the future of psychedelic medicine and its potential role in addressing unmet mental health needs.
As interest in the sector continues to expand, Melbourne is increasingly well positioned to serve as a meeting point for healthcare professionals, researchers, investors and organisations seeking to better understand the opportunities and challenges emerging within the field.
The International Psychedelic Roundtable Symposium aims to create a forum where scientific evidence, clinical experience, healthcare policy and investment perspectives can be discussed openly and professionally.
The event is expected to attract delegates from across Australia, New Zealand, North America, Europe and the broader Asia-Pacific region. Organisers are targeting attendance of approximately 150 to 200 delegates for the inaugural symposium, with ambitions to establish the event as a recurring fixture on the Asia Pacific healthcare and mental health conference calendar.
The program will feature keynote presentations, expert panel discussions and networking opportunities designed to connect psychiatrists, psychologists, researchers, healthcare leaders, founders, investors, policymakers and media professionals operating across one of the fastest-evolving areas of healthcare.
Alongside clinical and scientific discussions, the symposium will also examine the growing influence of capital markets, entrepreneurship, biotechnology, healthcare innovation and specialist media in shaping the future development of psychedelic medicine globally.
Spokesman for PRS 27 team , said the symposium was being launched at a pivotal moment for both Australia’s mental health sector and the international psychedelic medicine industry.
“Australia has become one of the most closely watched countries in the world when it comes to psychedelic assisted therapies. Researchers, clinicians, investors and policymakers are all looking closely at what happens next, and we believe Melbourne is the ideal place to bring those conversations together.”
“The International Psychedelic Roundtable Symposium is being designed as a meeting place for psychiatrists, psychologists, researchers, healthcare leaders, investors and media from across Australia and overseas. Our objective is to facilitate meaningful discussions that help shape the future of mental healthcare while fostering collaboration between the people and organisations driving innovation across the sector.”
“We are building more than a conference. We are creating a platform that connects science, clinical practice, investment, policy and industry. The opportunity ahead is significant, and the conversations taking place over the next few years will play an important role in determining how these therapies are researched, regulated, funded and ultimately delivered to patients.”
“We hope this becomes a flagship annual event for the Asia Pacific region and contributes to Melbourne’s reputation as a global centre for medical research, mental health innovation and healthcare leadership.”
Beyond its healthcare and educational objectives, the symposium is expected to generate interstate and international visitation while contributing to Melbourne’s visitor economy through accommodation, hospitality, transport and business tourism expenditure.
The event is hosted by Psychedelics.Media, an independent publication covering developments in psychedelic medicine, mental health innovation, neuroscience, clinical research, healthcare policy and emerging companies operating across the sector.
Early Bird Registrations Now Open
Student Pass
Early Bird: AUD $295
Standard: AUD $495
Valid student identification required.
General Admission
Early Bird: AUD $495
Standard: AUD $695
VIP Experience
Early Bird: AUD $995
Standard: AUD $1,495
VIP delegates will receive access to an exclusive speaker, sponsor and industry networking dinner following the symposium.
Organisations interested in sponsorship opportunities, speaking positions, exhibition space or strategic partnerships are encouraged to contact the organisers.
For further information, registrations and sponsorship enquiries, visit:
Psychedelics.Media
